Novel Carriers for Psoriasis Management and Pharmacotherapy

The ancestral form of immune-mediated ailments, psoriasis, can affect the joints, the skin, or both. An interdisciplinary team of professionals with diverse expertise is often necessary to effectively treat the disease. Several challenges are associated with psoriasis, including its high frequency, chronicity, disability, and the coexisting medical disorders that often accompany it. Understanding the importance of immune regulation in psoriasis, along with the interactions between the innate and adaptive branches of the immune system, has been instrumental in controlling the progression of this multifaceted disease, which affects individuals in ways that go beyond skin involvement. Psoriasis is a widespread skin condition that causes both emotional and physical suffering. Like other dermatoses, visible disfigurement may cause an increasingly undesirable response in others, which can account for a large portion of the disease's noticeable psychological stress. The present day disease demand has been exacerbated by several coexisting issues and including the syndrome of metabolism and cardiovascular conditions brought on by the syndrome. Certain environmental risk factors, including trauma (e.g., the Koebner phenomenon), infection, and medication, have been linked to the development of this inflammatory skin disorder. Psoriasis of the plaque type is distinguished by itchy plaques covered with silvery scales. Both adaptive and innate immune responses can contribute to psoriatic inflammation; however, innate immune responses appear to be more prevalent in psoriasis, regardless of plaque type. Comorbid diseases comprise psoriatic arthritis, the metabolic syndrome or its components, cardiovascular issues, and a host of additional conditions, including depression and anxiety, nonalcoholic fatty liver, Crohn's disease, and cancer.

Psoriasis, a papulosquamous skin disease, is estimated to affect 2% of the global population. Traditionally believed to be a problem largely affecting keratinocytes in the epidermis, psoriasis has recently been identified as one of the most common immune-related diseases. Though this condition may manifest at any life stage, a dual distribution of age was observed, having a peak occurring between the ages of 20 and 30 as well as 50 and 60. Psoriasis possesses a complicated etiology that includes immunologic, hereditary, and systemic/local factors. Psoriasis shows an immense negative impact on human life quality, probably equivalent in comparison to coronary artery disease, type 2 diabetes, depressive disorders, and carcinoma, regardless of the fact that it usually possesses a minor influence on survival. The unregulated development of keratinocytes is the main constraint behind psoriasis, and improper regulation of the immune system serves as a pathophysiological factor. The pathogenesis generally includes the cooperation among several populations for immunocytes along with corresponding transmitting molecules that are: (1) innate immunocytes, which are mediated by antigenic-displaying cells, such as neutrophils, the cells of Langerhans, and natural-killing T lymphoid cells (2) acquired or adaptable immunocytes, which are facilitated by developed CD4+ and CD8+ T lymphocyte residing in the epidermis. The result of such immunological dysfunction leads to inflammation, which causes clinical lesions as well as histopathological inflammation, diagnostic of psoriasis development and perpetuation. The standard of lifestyle in patients has increased with biologic treatments, which focus on the cytokine-mediated pathophysiology of psoriasis. This book chapter will cover the molecular basis and primary pathophysiology of psoriasis.

Psoriasis is a prominent autoimmune condition characterized by an abnormal increase in the production of skin cells, leading to the formation of thick, red, and scaly patches on the skin. Comprehending the intricate pathophysiology of this condition, which involves the deregulation of the immune system and inflammatory processes, is essential for the development of efficacious treatments. Existing treatment modalities, such as monotherapy, have inherent constraints in effectively managing psoriasis of moderate to severe intensity, resulting in persistent symptoms and reduced responsiveness to treatment. Therefore, using a combination strategy that focuses on various disease-causing pathways provides improved effectiveness in treatment, decreases the development of resistance, and improves patient outcomes. Nevertheless, it is crucial to carefully evaluate issues such as personalized treatment regimens, adherence to therapy, economic factors, and the handling of medication interactions and toxicities. Customized treatment methods, novel combination medications, and integrated therapy platforms have the potential to maximize psoriasis control. Thorough and personalized combination approaches hold great promise for improving the quality of life for individuals with psoriasis.

Psoriasis is a long-lasting autoimmune dermatological disorder affecting millions of individuals globally, causing substantial physical and psychological distress. While various treatment options, including topical creams, phototherapy, and systemic medications, resulted in relief for several sufferers, a significant portion of those affected by psoriasis remains inadequately treated. In recent years, gene therapy has emerged as a promising frontier in the field of dermatology, offering the potential for more effective and targeted treatments. This chapter reviews the current landscape of gene therapies for the management of psoriasis. It explores the underlying genetic factors contributing to psoriasis susceptibility, emphasizing the role of the immune system and the dysregulation of keratinocyte proliferation. The chapter also explores the various gene therapy approaches being developed to target these specific mechanisms. Recent advancements in gene editing technologies, such as CRISPR-Cas9, have paved the way for precise and targeted modification of genes associated with psoriasis. Researchers are developing strategies to either suppress overactive immune responses or correct genetic mutations that contribute to the pathogenesis of psoriasis. Promising preclinical and clinical results suggest that gene therapies hold the potential to provide long-lasting relief and even a cure for some patients. While gene therapy for psoriasis is still in its experimental stages, early trials have shown encouraging results with minimal side effects. It is essential to acknowledge the challenges and ethical considerations associated with gene therapy, including the need for rigorous safety and efficacy assessments. In conclusion, gene therapies offer a promising avenue for treating psoriasis, with the potential to revolutionize the management of this chronic condition. Ongoing research and clinical trials will determine the safety and effectiveness of these innovative approaches, ultimately providing hope for those suffering from psoriasis and paving the way for personalized, precision medicine in dermatology. 

Psoriasis is an autoimmune disease that re-emerges through the proliferation of keratinocytes. It occurs at any age, but is usually observed in temperate regions. It has a global population of 2 to 5 percent on average. The treatment of psoriasis remains a daunting task, with various challenges affecting treatment, including patient compliance and adherence, delicate patient profiles, psychological aspects, and skin as an obstacle to current delivery. Psoriasis is characterized by an excessive proliferation of cells, resulting in painful skin spots due to the absence of normal skin cell replacement, which occurs every 3 to 4 weeks. Treatment strategies for psoriasis depend on the severity and location of the injuries. The current chapter reviews the therapies and challenges associated with current treatments, including topical therapy, oral therapy, biological therapy, parenteral therapy, and phototherapy. 

Psoriasis is a globally prevalent chronic inflammatory condition. Traditional treatment methods often rely on immunosuppressive agents, which can have adverse effects on the human body. As a result, alternative therapies, particularly those utilizing phytoconstituents with immunomodulatory, antioxidant, and anti-inflammatory properties, have gained attention. This chapter explores the potential of medicinal plants and phytoconstituents in managing psoriasis symptoms and supporting long-term disease control. However, to fully harness the therapeutic benefits of these plantderived compounds and integrate them into standard dermatological care for psoriasis patients, further research and rigorous clinical validation are essential. 

The chronic inflammatory skin disease, psoriasis, affects a large number of people globally. It is typified by immune system malfunction that results in a range of symptoms. The primary goal of conventional drug delivery methods for psoriasis treatment is to alleviate symptoms; however, these methods frequently fall short due to their poor safety and efficacy, low bioavailability, and limited effectiveness. Consequently, there has been an increase in interest in creating innovative drug delivery systems that might overcome these drawbacks. Liposomes, transferosomes, ethosomes, niosomes, emulsomes, dendrimers, hydrogels, nanoparticles, and others are examples of these novel drug delivery methods. Through modifications to pharmacokinetic and physiological factors, these formulations aim to enhance the therapeutic effects of medications. Liposomes are one of these systems that are the most promising for delivering medications to treat psoriasis. Liposomes are lipid bilayer-based tiny vesicles that can enhance the penetration of medications through the stratum corneum, the outermost layer of the skin. When applied topically, this increased penetration can improve the delivery of medications into or through the skin. Improved therapeutic results are a result of liposomes' many benefits, which include longer drug release and enhanced stability. The potential of liposomes as a drug delivery mechanism for treating psoriasis is the main topic of this chapter. By encapsulating anti-psoriatic medications inside liposomes, researchers aim to enhance treatment efficiency and target areas affected by psoriasis. Treating psoriasis with liposomes has the potential to enhance patient outcomes by overcoming the limitations of traditional drug delivery methods. In conclusion, the development of innovative medication delivery methods, such as liposomes, offers a viable strategy for managing psoriasis. Through the utilisation of liposomes' distinct characteristics, such as their enhanced drug penetration and extended release, scientists aim to augment the therapeutic outcomes of pharmaceuticals and improve the overall treatment of psoriasis.

Background: Psoriasis is a long-term autoimmune disease that causes skin cells to develop quickly, resulting in thick, red, scaly areas on the skin's surface. The itchiness and pain associated with these patches can significantly impact the quality of life for those affected. The primary objectives of psoriasis therapy are to reduce inflammation, inhibit excessive skin cell growth, and alleviate symptoms.

Objective: Despite ongoing research efforts, patient satisfaction with existing topical therapies for psoriasis remains limited. There is a pressing need to enhance the safety, efficacy, and comfort of topical therapies by developing innovative drug delivery and carrier systems.

Method: Using niosomes, which are non-ionic surfactant-based vesicles that can encapsulate both hydrophilic and hydrophobic medications, is one intriguing strategy. The pharmaceutical industry has shown considerable interest in niosomes due to their potential to reduce toxicity and enhance therapeutic efficacy. With low toxicity and optimal targeting efficacy, these vesicles provide a unique method of delivering a variety of therapeutic agents, including chemical drugs, protein-based therapies, and genetic materials.

Results: Studies have reported that niosomes can increase drug bioavailability and stability, making them a viable option for drug delivery in the treatment of psoriasis. Compared to conventional topical treatments, niosomes offer improved stability during formulation and storage, which may lead to enhanced therapeutic outcomes and increased patient satisfaction.

Conclusion: The use of niosomes represents a promising approach to enhancing topical therapy in the management of psoriasis. Their capacity to minimize toxicity and encapsulate a variety of medications, including hydrophilic and hydrophobic agents, makes them a desirable choice for improving the comfort, safety, and efficacy of psoriasis therapy. Continued research and development in this field could significantly advance the treatment of psoriasis and other dermatological conditions.  

Psoriasis, a chronic autoimmune skin disorder, poses a significant therapeutic challenge due to its complex Etiology and variable clinical manifestations. This abstract highlights recent advancements in novel carrier systems that revolutionize psoriasis management and pharmacotherapy. These innovative carriers aim to improve drug delivery, enhance therapeutic efficacy, and mitigate the adverse effects of conventional treatments. Psoriasis is characterised by hyperproliferation of keratinocytes, inflammation, and immune dysregulation. Conventional treatments often involve topical corticosteroids, phototherapy, or systemic immunosuppressants, each with its limitations, such as variable efficacy and side effects. The emergence of novel carrier systems, including liposomes, nanoparticles, and microneedle arrays, provides a promising avenue for addressing these challenges. Advanced drug delivery systems enable the precise delivery and management of the release of therapeutic agents, enhancing their penetration into the affected skin layers. Liposomal formulations, for instance, offer improved drug stability and sustained release, minimizing the need for frequent applications and reducing side effects. Nanoparticles provide a platform for encapsulating various drugs, offering enhanced solubility and bioavailability. Moreover, the integration of personalized medicine approaches into carrier design allows for tailored treatment regimens based on individual patient characteristics. This shift towards precision medicine holds the potential to optimize therapeutic outcomes and minimize adverse reactions.

 Psoriasis is a chronic skin condition characterized by the hyperproliferation of keratinocytes in the epidermis, resulting in a high turnover rate of the epidermal cells. Apart from its physical manifestations, it also impacts an individual's psychological well-being. Its symptoms, such as pain, itching, and peeling, are more severe than those of other diseases, leading to a higher prevalence of depression and anxiety. Nanosponges are versatile nanoparticle platforms with porous, threedimensional structures that can effectively encapsulate and deliver a wide range of drugs and bioactive molecules, owing to their distinct capabilities, including controlled release patterns and the ability to target delivery. In this review, the advantages of nanosponges as a drug delivery system for treating the disease will be discussed.

Psoriasis is a chronic inflammatory skin disorder affecting millions worldwide, posing significant therapeutic challenges due to its complex pathophysiology and diverse clinical manifestations. Conventional treatment options often yield suboptimal results and are associated with adverse effects, highlighting the need for innovative therapeutic strategies. Polymeric nanoparticles [PNPs] have emerged as a promising approach, offering enhanced drug bioavailability, sustained release, and reduced systemic toxicity. This chapter provides a comprehensive overview of the application of PNPs in psoriasis management, emphasizing their advantages over conventional therapies. By addressing the limitations of existing treatments, PNPs offer a viable strategy for enhancing therapeutic outcomes and improving patient care in psoriasis management.

Psoriasis, a chronic inflammatory skin disease, presents a significant therapeutic challenge. Conventional treatments often exhibit limited efficacy and adverse effects. This chapter examines the potential of metallic nanoparticles as a promising approach for managing psoriasis. By harnessing the unique properties of these nanoparticle-based pharmacotherapies, researchers have developed innovative drug delivery systems and therapeutic strategies. These nanoparticles offer advantages such as enhanced drug bioavailability, targeted delivery, and sustained release, leading to improved clinical outcomes. This chapter discusses the current state-of-the-art in metallic nanoparticle-based therapies for psoriasis, highlighting their mechanisms of action, potential benefits, and challenges. Furthermore, this chapter emphasizes the importance of addressing safety and toxicity concerns associated with metallic nanoparticles. While preclinical studies have demonstrated promising results, rigorous evaluation of their long-term effects and biocompatibility is crucial before widespread clinical application. Future research should focus on optimizing nanoparticle formulations, exploring combination therapies, and conducting well-designed clinical trials to establish the efficacy and safety of these nanomaterials in psoriasis management. 

Psoriasis is a chronic inflammatory skin disease in which over-activation of the immune system (T-cells, keratinocytes) leads to dilation of dermal capillaries of the epidermis and dermis due to excessive production of cytokines. It is primarily characterized by erythematous, itchy, and scaly patches on the exposed surfaces of the body, mainly the scalp, elbows, and knees. Environmental factors, genetics, bacterial infections, etc., also play a significant role in its occurrence. Numerous therapies like acupuncture, water therapy, phototherapy, meditation, herbal treatment, moisturizing treatment, use of nutritional supplements, and different drug formulations for topical (salicylic acid, dithranol, vitamin D, corticosteroids, tacrolimus) and systemic (methotrexate, cyclosporine, acitretin) use are beneficial in its management. Topical therapies, due to the skin’s barrier effect, have poor penetration and absorption; therefore, to provide more controlled, targeted, nontoxic, secure drug delivery, nanoformulations are used nowadays. Local administration of drug-loaded nanocarriers, viz. liposomes, niosomes, ethosomes, nanoemulsions, transferosomes, etc. demonstrated improved penetrability and effectiveness at lesser doses while causing little systemic side effects. Ethosomes are emerging lipid vesicular nanocarriers containing phospholipids along with relatively high amounts of alcohol (mainly ethanol), which are responsible for the penetration of entrapped drugs (having diverse physicochemical parameters) deep into the skin. Because of their high safety, efficacy, stability, patient compliance, and simple manufacturing procedures, ethosomes act as one of the effective carriers for transdermal drug delivery. Various drug-containing ethosomes have been successfully designed and evaluated for the pharmacotherapy of psoriasis. Therefore, in this chapter, the main focus is to collate all the ethosomesbased drug formulations designed for the management of psoriasis. 

The autoimmune condition psoriasis is typified by hyperproliferation of keratinocytes, lesions, and silver-white scales inside the epidermis. Environmental and genetic factors both contribute to its cause. For psoriasis, several medication targets and focused treatments have been discovered. To lessen the symptoms of this illness, numerous target-specific medicines have also been created. Psoriasis is being treated using a variety of techniques, such as herbal remedies, nano-carrier therapy, and conventional therapy. In this regard, delivery through the transdermal route is an intriguing choice because it is safe and convenient. Since transferosomes have a bilayered structure that makes it easier to encapsulate lipophilic, hydrophilic, and amphiphilic drugs with higher penetration efficiencies than regular liposomes, they are a popular option for transdermal medication delivery for psoriasis. Because of their flexibility, they can flex and sneak through small pores that are significantly smaller than their actual dimensions, while remaining intact as a whole vesicle. This chapter aims to explain the concept of transferosomes, their mode of action, various methods of preparation, and their current applications in psoriasis therapy.

Background: Psoriasis is an inflammatory, autoimmune skin condition that is driven by T cells & is characterized by abnormal keratinization, hyperkeratosis, angiogenesis, and inflammation of the skin's surface. There are now many different pharmacotherapies for it; nevertheless, standard formulation-based pharmacotherapy can only partially improve treatment outcomes. Recent developments in nanomedicine based on nanotechnology may make pharmacotherapeutic drugs for psoriasis more safe and effective.

Objective: The objective is to offer a comprehensive overview of the development & utilization of emulsomes for targeted delivery of anti-psoriatic agents. This addresses the various drugs, the pathophysiology of psoriasis in short, and the therapeutic issues that come with it. Below, we have discussed the collective reports of several medications operating on distinct psoriasis molecular targets as well as the function of nanomedicine in their efficient targeting.

Methods: The formulation techniques involved in preparing emulsomes loaded with anti-psoriatic drugs highlight the key parameters considered for their optimization. Various methods for characterizing emulsomes, such as particle size analysis, encapsulation efficiency determination, & surface morphology examination, are elaborated. The in vitro & in vivo experimental methods employed to assess drug release, skin permeation, and therapeutic efficacy are also detailed.

Results: Emulsomes-based formulations demonstrated superior encapsulation efficiency, sustained drug release, and enhanced skin penetration, leading to improved therapeutic outcomes in psoriasis management. Experimental findings and comparative analyses reveal the advantages of emulsomes over conventional drug delivery systems.

Conclusion: Emulsomes-based pharmacotherapy presents a promising approach for targeted and efficient management of psoriasis. The chapter focuses on emphasizing emulsomes' potential to revolutionize psoriasis treatment paradigms and highlighting future research directions in this field.

The word “psoriasis” comes from the Ancient Greek word “psora,” which means “itch.” Severe itching is a common symptom of psoriasis, a chronic, noncontagious, inherited skin condition. It is an immune-mediated condition characterised by both hyperproliferation and inadequate keratinocyte differentiation in the epidermis of the skin. Although only affecting 2-3% of the population, this immune-mediated skin condition has a major harmful effect on the patient's quality of life. Although they have demonstrated poor efficacy and lack aesthetic value, topical psoriatic therapies such as emollients, coal tar, and dithranol are safer. Many strategies have been investigated by modern medicine to treat this condition (such as injectables, oral medication, and steroid-based lotions). However, none of these approaches have proven successful, as they lack an ideal and safe carrier that can deliver the antipsoriatic medication to the patient safely and effectively, thereby achieving the greatest possible therapeutic impact. Researchers are working with nanotechnology to overcome the shortcomings of traditional treatments, aiming to improve the effectiveness of anti-psoriatic drug delivery and reduce its unfavourable side effects.

Utilising a colloidal model, nanoemulsion is a technique that applies high surface area active substances in the form of nanosized droplets to the skin's afflicted area. A number of advantages over traditional delivery methods are provided by nanoemulsions, which include decreased drug degradation and loss, avoided hazardous side effects, and higher drug bioavailability. Compared to coarse emulsions, nanoemulsions exhibit greater kinetic stability, prevent cream separation, significantly influence topical systems, and have a higher solubilization capacity.

Significant research on nanoemulsion-loaded antipsoriatic medicines has previously been done. Many antipsoriatic drugs, including Capsaicin, Aceclofenac, Turmeric oil, Calcipotriol, Betamethasone Dipropionate, salicylic acid, Clobetasol propionate and others have been loaded into nanoemulsion using various preparation methods. 

Psoriasis is a serious dermal plight characterised by inflammation and hyper-proliferation of the keratinized cells of the epidermis. Because of the complicated disposition of the disease, it has a severe pessimistic impact on the patient's overall well-being. Currently, a variety of medications are available for treating psoriasis, including conventional topical therapies, UVB therapy, intrinsic or systemic immune-modulators, and biologics, which aim to alleviate symptoms and thereby improve the quality of life for patients. Conventional topical therapies, though they constitute first-line therapy, have restricted efficacy because of the mediocre drug penetration properties, deposition, and dose-related toxicity. The latest progression in topical treatments, specifically with micro-scaled medical devices like micro-needles and nanoparticle-based carriers, lipid nanoparticles offer a promising future with significantly better therapeutic potency as it has a way better skin permeation, controlled release of the drug, targeting specific pathways, such as IL-23 inhibitors like mirikizumab and RORγt inhibitors, hence contributing to better drug delivery and efficacy for psoriatic plaques. These innovative and efficient therapies may cut down the side effects and may lead to improved and better patient adherence. 

Psoriasis, a chronic autoimmune skin condition that affects millions of people worldwide, is becoming more common because of modern lifestyle variables like stress, unhealthy eating habits, and pollution in the environment. This chapter explores the intricate relationship between illness and modern living, focusing on the management of psoriasis through dietary changes, lifestyle adjustments, and holistic approaches. It explores the effects of processed foods, inflammatory triggers, and gut health, emphasizing the value of nutritional methods and anti-inflammatory diets. The chapter also looks at alternative medicines like Ayurveda and Traditional Chinese Medicine and stress-reduction methods like yoga and mindfulness. This chapter offers a thorough manual for anyone looking for a natural, well-rounded approach to managing psoriasis in today's fast-paced world by fusing scientific knowledge with useful suggestions.